Acarbose
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Acarbose: From Type 2 Diabetes Mellitus to Focal Stiff Limb Syndrome
One-Sentence Summary
Acarbose was originally used to treat type 2 diabetes mellitus. The TxGNN model predicts it may be effective for focal stiff limb syndrome, but there are currently no clinical trials and no publications supporting this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus (the Canadian licence records contain no indication text) |
| Predicted New Indication | Focal stiff limb syndrome |
| TxGNN Prediction Score | 0.9965 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, acarbose is an alpha-glucosidase inhibitor that acts locally in the gut, and its efficacy in type 2 diabetes mellitus is established. It slows carbohydrate digestion and so reduces the rise in blood sugar after meals.
The link to focal stiff limb syndrome is weak. This is a rare neurological condition closely related to stiff person syndrome, which is typically autoimmune (often anti-GAD) and frequently occurs alongside diabetes. The model’s high score most likely reflects network proximity to diabetes-associated autoimmune neurological conditions, not a pharmacological relationship. Acarbose has no known effect on GABAergic signalling or on the autoimmune process, so the prediction should be treated as a hypothesis only.
The same pattern applies to the other top predictions (classic stiff person syndrome, thiamine-responsive dysfunction syndrome, opsismodysplasia, and several localized lipodystrophies). All are model predictions with no supporting trials or literature, and none has a plausible mechanistic link to acarbose.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for focal stiff limb syndrome.
The only publications retrieved were for a lower-ranked prediction, pancreatic agenesis (rank 9). They cover type 2 diabetes, beta-cell preservation, insulin autoimmune syndrome and animal models, and none addresses pancreatic agenesis directly. They therefore do not support the lead prediction.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02494086 | MAR-ACARBOSE | Not listed | Not listed |
| 02494078 | MAR-ACARBOSE | Not listed | Not listed |
Safety Considerations
Contraindication-related conditions (from the TxGNN knowledge graph, not label text): kidney disease, pyoureter, liver disease, gallbladder disease, cirrhosis of liver, inflammatory bowel disease, hypoglycemia, injury.
Drug Interactions: 100 interactions were identified in the DDInter database. The first 20 returned include:
- Moderate: acetazolamide, salbutamol, aloe vera leaf, alpelisib, amprenavir, aripiprazole, asenapine, asparaginase (Erwinia chrysanthemi and E. coli), atazanavir, bedaquiline, bendroflumethiazide, benzphetamine, benzthiazide, betamethasone
- Minor: albiglutide, alclometasone (topical), lipoic acid, amcinonide, anisindione
Many of the moderate interactions involve drugs that can raise blood glucose (such as corticosteroids, thiazides and some antipsychotics), which may reduce the glucose-lowering effect of acarbose. The full list of 100 interactions was not available for review.
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the TxGNN score, with no clinical trials or literature, so the evidence level is L5. No plausible pharmacological link exists between a gut alpha-glucosidase inhibitor and focal stiff limb syndrome.
To proceed, the following is needed:
- Mechanism of action data for acarbose, to allow a proper mechanistic analysis
- Health Canada package insert warnings and contraindications, which are required before any safety screening
- Any clinical or preclinical evidence linking acarbose to focal stiff limb syndrome or stiff person spectrum disorders
- Indication and dosage form details for the two Canadian DINs
- Reassessment of whether other predicted indications have better support
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.